Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients-Reference-Cited by-同舟云学术

Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients

Published:2021-08-02 Issue:4 Volume:39 Page:521-528
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Højholt Karen Louise¹,Gregersen Henrik²,Szabo Agoston Gyula³,Klausen Tobias Wirenfeldt⁴,Levring Mette Bøegh⁵,Preiss Birgitte⁶,Helleberg Carsten⁴,Breinholt Marie Fredslund⁷,Hermansen Emil⁸^ORCID,Rahbek Gjerdrum Lise Mette⁹¹⁰,Bønløkke Søren Thorgaard¹¹,Nielsen Katrine¹¹,Kjeldsen Eigil¹¹,Iversen Katrine Fladeland³,Teodorescu Elena Manuela²,Kurt Eva¹²,Strandholdt Casper¹³,Andersen Mette Klarskov¹⁴,Vangsted Annette Juul¹^ORCID

Affiliation:

1. Department of Haematology Rigshospitalet Copenhagen University Denmark

2. Department of Haematology Aalborg University Hospital Aalborg Denmark

3. Department of Haematology Vejle Hospital Vejle Denmark

4. Department of Haematology Herlev University Hospital Herlev Denmark

5. Department of Haematology Odense University Hospital Odense Denmark

6. Department of Pathology Odense University Hospital Odense Denmark

7. Department of Pathology Herlev University Hospital Herlev Denmark

8. Department of Haematology Zealand University Hospital Roskilde Denmark

9. Department of Pathology Zealand University Hospital Roskilde Denmark

10. Department of Clinical Medicine University of Copenhagen Denmark

11. Department of Haematology Aarhus University Hospital Aarhus Denmark